3611 Valley Centre Drive
About Travere Therapeutics
Even with the challenges all of us are facing as a result of COVID-19, Travere Therapeutics continues to come together as an organization to live our mission each day to support our patients and invest in our capabilities for the future. At the center of these efforts are our people. Travere remains committed to preventing interruption of our clinical programs, providing unwavering patient support and ensuring delivery of therapies to our patients. Moments like this are when our patients need us the most.
If you want to join a team that now more than ever lives its mission to the fullest extent, please review our current opportunities and apply to positions that may be of interest to you.
Travere is continuing to hire for all open roles with all interviewing and onboarding done virtually due to COVID-19.
Everyone new to the team, along with our current staff, will temporarily work from home until it is safe to return to our offices.
At Travere Therapeutics, formerly Retrophin, our number one priority will always be the patients we serve - they are “why” we come to work each day. Our Why is ingrained into our culture and is paramount to “what” we do every day and “how” we do it to achieve our mission of identifying, developing and delivering life-changing therapies to people living with rare disease. By working hard, supporting our team members and living our values of Accountability, Entrepreneurial Spirit, Integrity, Patient Focus, Scientific Excellence and Teamwork, we strive to help our organization succeed and pursue our vision - to become a preeminent, global and fully-integrated biopharmaceutical company within the rare disease community that is dedicated to giving patients a chance and providing hope.
Our pipeline features late-stage development programs targeting rare diseases with significant unmet medical needs including sparsentan for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), disorders characterized by progressive scarring of the kidney often leading to end-stage renal disease. In partnership with leaders in patient advocacy and government research, we are also working to identify potential therapeutics for NGLY1 deficiency and Alagille syndrome, rare conditions with no approved treatment options. Our R&D efforts are supported by revenues from our four commercial products Chenodal® (chenodiol), Cholbam® (cholic acid), Thiola® (tiopronin) and THIOLA EC™ (tiopronin) delayed-release tablets.
Through our portfolio of approved products and promising pipeline focused on hepatology, nephrology and neurology, we strive to help people achieve the best possible outcomes today and tomorrow. But most importantly, it is the commitment of our experienced, knowledgeable and compassionate team members, who put patients at the center of everything they do, that truly matters.
212 articles with Travere Therapeutics
Retrophin Announces Pivotal Phase 3 FORT Study of Fosmetpantotenate in PKAN Opens Enrollment to Pediatric Patients
Retrophin, Inc. (NASDAQ:RTRX) today announced that the independent Data Monitoring Committee (DMC) for the pivotal Phase 3 FORT Study, which is evaluating fosmetpantotenate for the treatment of pantothenate kinase-associated neurodegeneration (PKAN), has completed its scheduled clinical safety review required to open enrollment for pediatric patients.
Retrophin, Inc. (NASDAQ:RTRX) today announced that the Company’s management team will present at the following upcoming investor conferences in June.
Retrophin, Inc. (NASDAQ:RTRX) today announced that it has been awarded the Peter Barron Stark Companies (PBS) Award for Workplace Excellence.
Retrophin, Inc. (NASDAQ:RTRX) today reported its first quarter 2018 financial results and provided a corporate update.
Retrophin, Inc. (NASDAQ:RTRX) today announced it will report first quarter 2018 financial results on Tuesday, May 1, 2018 after the close of the U.S. financial markets.
Retrophin Initiates Pivotal Phase 3 Clinical Trial of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis
Retrophin, Inc. (NASDAQ:RTRX) today announced that the first patient has been enrolled in the DUPLEX Study, a global, pivotal Phase 3 clinical trial.
Retrophin, Inc. (NASDAQ:RTRX) today announced that Casey Logan has joined the Company as vice president, corporate development.
Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage, chief executive officer, will present at the Barclays Global Healthcare Conference in Miami on Wednesday, March 14, 2018 at 3:50 p.m. ET.
Retrophin Recognizes Rare Disease Day® 2018 and Joins Others Worldwide to Raise Awareness About Rare Diseases
Retrophin, Inc. (NASDAQ: RTRX) today joins the National Organization for Rare Disorders (NORD), the European Organisation for Rare Diseases (EURORDIS), and rare disease advocates and patients worldwide to recognize Rare Disease Day® 2018.
Retrophin, Inc. (NASDAQ:RTRX) today reported its fourth quarter and full year 2017 financial results and provided a corporate update.
Retrophin, Inc. (NASDAQ:RTRX) today announced it will report fourth quarter and full year 2017 financial results on Tuesday, February 27, 2018 after the close of the U.S. financial markets.
Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage, chief executive officer, will present at the Leerink Partners 7th Annual Global Healthcare Conference in New York City on Thursday, February 15, 2018 at 9:00 a.m. ET.
Children's National Health System and Retrophin are pleased to announce the creation of the Retrophin Rare Disease Network at Children's National.
Preliminary full-year 2017 revenue of approximately $155 million.
Retrophin and Censa Pharmaceuticals Enter Into Strategic Collaboration to Advance CNSA-001 for the Treatment of Phenylketonuria (PKU)
Retrophin obtains exclusive option to purchase Censa post proof-of-concept study.
Net product sales for the third quarter of 2017 were $40.3 million, compared to $33.9 million for the same period in 2016.
Retrophin Reports Additional Positive Data from Open-Label Extension of Phase II DUET Study of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis (FSGS)
These data were presented today during an oral session at the American Society of Nephrology (ASN) Kidney Week 2017 in New Orleans, LA.
The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.
Retrophin Announces Presentation Of New Data From Physician-Initiated Treatment With Fosmetpantotenate At The Child Neurology Society’s 26th Annual Meeting
Retrophin Announces Cooperative Research And Development Agreement With NCATS And NGLY1.org To Identify Potential Small Molecule Therapeutics For NGLY1 Deficiency